Modulated-splitting-ratio fiber-optic temperature sensor

A fiber-optic temperature sensor is described, which uses a small silicon beamsplitter whose splitting ratio varies as a function of temperature. A four-beam technique is used to measure the sensor's temperature-indicating splitting ratio. This referencing method provides a measurement that is largely independent of the transmission properties of the sensor's optical fiber link. A significant advantage of this sensor, relative to other fiber-optic sensors, is its high stability, which permits the fiber-optic components to be readily substituted, thereby simplifying the sensor's installation and maintenance

Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophrenia

Objective: To evaluate health care resource utilization in patients with schizophrenia who continued newly prescribed antipsychotic medications, compared with those switching to different treatments. Methods: Adults with schizophrenia in the California Medicaid (MediCal) database who initiated treatment with index medications in 1998–2001, were classified as having: 1) abandoned antipsychotic medications; 2) switched to another medication; or 3) continued with the index antipsychotic, for up to 6 months after the index date. Results: Of 2300 patients meeting eligibility criteria, 1382 (60.1%) continued index medications, 480 (20.9%) switched, and 438 (19.0%) abandoned antipsychotic treatment. Utilization in several resource categories occurred significantly more frequently among patients whose regimens were switched (vs those continuing index medications). These included using psychiatric (24.2% vs 14.5%; P \u3c 0.001) or nonpsychiatric (31.5% vs 24.3%; P \u3c 0.05) emergency services; being admitted to a hospital (10.6% vs 7.4%; P \u3c 0.05); making nonpsychiatric outpatient hospital visits (43.3% vs 36.4%; P \u3c 0.05) or nonpsychiatric physician visits (62.7% vs 56.4%; P \u3c 0.05); and using other outpatient psychiatric (53.3% vs 40.7%; P \u3c 0.001) or nonpsychiatric (82.7% vs 74.6%; P \u3c 0.001) services. Conclusions: Switching antipsychotic medications is associated with significantly increased health care resource utilization (vs continuing treatment)

NASA-UVA Light Aerospace Alloy and Structures Technology Program: LA(2)ST

The NASA-UVA Light Aerospace Alloy and Structures Technology (LA(2)ST) Program continues a high level of activity, with projects being conducted by graduate students and faculty advisors in the Departments of Materials Science and Engineering, Civil Engineering and Applied Mechanics, and Mechanical and Aerospace Engineering at the University of Virginia. This work is funded by the NASA-Langley Research Center under Grant NAG-1-745. We report on progress achieved between July 1 and December 31, 1992. The objective of the LA(2)ST Program is to conduct interdisciplinary graduate student research on the performance of next generation, light weight aerospace alloys, composites and thermal gradient structures in collaboration with NASA-Langley researchers. Specific technical objectives are presented for each research project. We generally aim to produce relevant data and basic understanding of material mechanical response, corrosion behavior, and microstructure; new monolithic and composite alloys; advanced processing methods; new solid and fluid mechanics analyses; measurement advances; and critically, a pool of educated graduate students for aerospace technologies

NASA-UVA light aerospace alloy and structures technology program

The report on progress achieved in accomplishing of the NASA-UVA Light Aerospace Alloy and Structures Technology Program is presented. The objective is to conduct interdisciplinary graduate student research on the performance of next generation, light weight aerospace alloys and associated thermal gradient structures in close collaboration with researchers. The efforts will produce basic understanding of material behavior, new monolithic and composite alloys, processing methods, solid and fluid mechanics analyses, measurement advances, and a pool of educated graduate students. The presented accomplishments include: research on corrosion fatigue of Al-Li-Cu alloy 2090; research on the strengthening effect of small In additions to Al-Li-Cu alloys; research on localized corrosion of Al-Li alloys; research on stress corrosion cracking of Al-Li-Cu alloys; research on fiber-matrix reaction studies (Ti-1100 and Ti-15-3 matrices containing SCS-6, SCS-9, and SCS-10 fibers); and research on methods for quantifying non-random particle distribution in materials that has led to generation of a set of computer programs that can detect and characterize clusters in particles

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)

BACKGROUND: This phase 2 trial was designed to evaluate the efficacy of vorinostat in chemotherapy-pretreated patients with metastatic castration-resistant prostate cancer. METHODS: Patients with disease progression on 1 prior chemotherapy, a prostate-specific antigen (PSA) ≥5 ng/mL, and adequate organ function were treated with 400 mg vorinostat orally daily. The primary endpoint was the 6-month progression rate. Secondary endpoints included safety, rate of PSA decline, objective response, overall survival, and effects of vorinostat on serum interleukin-6 (IL-6) levels. RESULTS: Twenty-seven eligible patients were accrued. The median number of cycles delivered was 2 (range, 1-7). All patients were taken off therapy before 6 months. The best objective response in the eligible patient was stable disease in 2 (7%) patients. No PSA decline of ≥50% was observed. There was 1 grade 4 adverse event (AE), and 44% of patients experienced grade 3 adverse events. The most common adverse events were fatigue (81%), nausea (74%), anorexia (59%), vomiting (33%), diarrhea (33%), and weight loss (26%). Median time to progression and overall survival were 2.8 and 11.7 months, respectively. Median IL-6 levels (pg/mL) were higher in patients removed from the protocol for toxicity compared with progression at all time points, including baseline (5.2 vs 2.1, P = .02), Day 15 Cycle 1 (9.5 vs 2.2, P = .01), Day 1 Cycle 2 (9.8 vs 2.2, P = .01), and end of study (11.0 vs 2.9, P = .09). CONCLUSIONS: Vorinostat at this dose was associated with significant toxicities limiting efficacy assessment in this patient population. The significant association between IL-6 levels and removal from the study for toxicities warrants further investigation. Cancer 2009. © 2009 American Cancer Society.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/64445/1/24597_ftp.pd

Polycyclic Aromatic Hydrocarbon and Mid-Infrared Continuum Emission in a z > 4 Submillimeter Galaxy

We report the detection of 6.2 μm polycyclic aromatic hydrocarbon (PAH) and rest-frame 4-7 μm continuum emission in the z = 4.055 submillimeter galaxy GN20, using the Infrared Spectrograph on board the Spitzer Space Telescope. This represents the first detection of PAH emission at z > 4. The strength of the PAH emission feature is consistent with a very high star formation rate of ~1600 M☉ yr^(–1). We find that this intense starburst powers at least ~1/3 of the faint underlying 6 μm continuum emission, with an additional, significant (and perhaps dominant) contribution due to a power-law-like hot dust source, which we interpret to likely be a faint, dust-obscured active galactic nucleus (AGN). The inferred 6 μm AGN continuum luminosity is consistent with a sensitive upper limit on the hard X-ray emission as measured by the Chandra X-Ray Observatory if the previously undetected AGN is Compton-thick. This is in agreement with the finding at optical/infrared wavelengths that the galaxy and its nucleus are heavily dust-obscured. Despite the strong power-law component enhancing the mid-infrared continuum emission, the intense starburst associated with the photon-dominated regions that give rise to the PAH emission appears to dominate the total energy output in the infrared. GN20 is one of the most luminous starburst galaxies known at any redshift, embedded in a rich protocluster of star-forming galaxies. This investigation provides an improved understanding of the energy sources that power such exceptional systems, which represent the extreme end of massive galaxy formation at early cosmic times

Occupational Exposure to Pfiesteria Species in Estuarine Waters Is Not a Risk Factor for Illness

BACKGROUND: Exposure to the dinoflagellate Pfiesteria has, under certain circumstances, been associated with deficits in human learning and memory. However, uncertainties remain about the health risk of chronic, low-level exposures (as seen among occupationally exposed commercial fishermen), particularly in light of studies suggesting that Pfiesteria strains are widespread in the estuarine environment in the U.S. mid-Atlantic region. METHODS: We selected an initial cohort of 152 persons, including 123 persons with regular, occupational exposure to the Chesapeake Bay; 107 of the cohort members were followed for the full four summer “seasons” of the study. Cohort members were questioned biweekly about symptoms, and data were collected about the areas of the bay in which they worked. These latter data were matched with data on the presence or absence of Pfiesteria in each area, based on polymerase chain reaction analysis of > 3,500 water samples. Cohort members underwent neuropsychological testing at the beginning and end of each summer season. RESULTS: No correlation was found between work in an area where Pfiesteria was identified and specific symptomatology or changes on neuropsychological tests. CONCLUSIONS: Although high-level or outbreak-associated exposure to Pfiesteria species (or specific strains within a species) may have an effect on health, routine occupational exposure to estuarine environments in which these organisms are present does not appear to pose a significant health risk